Yardley-based Optinose, which put itself up for auction three years ago attracting multiple suitors, has secured a potential ...

Bucks County specialty pharmaceutical company Optinose first started exploring mergers and licensing deals in early 2022.

Triggering the acquisition was a label expansion for Xhance, which was originally approved in 2017 for patients with CRS and nasal polyps. An FDA nod 12 months ago allows it to be used by those ...

XHANCE is an innovative, drug-device combination product approved for the treatment of CRS with or without nasal polyps. By optimally targeting the site of inflammation with a proven ...

Xhance is an innovative drug-device therapy for chronic rhinosinusitis (CRS), with or without nasal polyps. Utilizing its proprietary Exhalation Delivery System, it delivers a corticosteroid ...

XHANCE is an innovative, drug-device combination product approved for the treatment of CRS with or without nasal polyps. By optimally targeting the site of inflammation with a proven corticosteroid ...